CR9849A - Agonistas del receptor gamma activado por el proliferador de peroxisomas para la mejora de la funcion cognitiva en pacientes con apolipoproteina e4 negativa - Google Patents
Agonistas del receptor gamma activado por el proliferador de peroxisomas para la mejora de la funcion cognitiva en pacientes con apolipoproteina e4 negativaInfo
- Publication number
- CR9849A CR9849A CR9849A CR9849A CR9849A CR 9849 A CR9849 A CR 9849A CR 9849 A CR9849 A CR 9849A CR 9849 A CR9849 A CR 9849A CR 9849 A CR9849 A CR 9849A
- Authority
- CR
- Costa Rica
- Prior art keywords
- cognitive function
- apolipoprotein
- patients
- negative
- improvement
- Prior art date
Links
- 230000003920 cognitive function Effects 0.000 title abstract 2
- 108010060159 Apolipoprotein E4 Proteins 0.000 title 1
- 210000002824 peroxisome Anatomy 0.000 title 1
- 239000000018 receptor agonist Substances 0.000 title 1
- 229940044601 receptor agonist Drugs 0.000 title 1
- 108700028369 Alleles Proteins 0.000 abstract 2
- 206010012289 Dementia Diseases 0.000 abstract 1
- 229940080774 Peroxisome proliferator-activated receptor gamma agonist Drugs 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US71935305P | 2005-09-22 | 2005-09-22 | |
| US72737705P | 2005-10-17 | 2005-10-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR9849A true CR9849A (es) | 2008-05-21 |
Family
ID=37876831
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR9849A CR9849A (es) | 2005-09-22 | 2008-03-28 | Agonistas del receptor gamma activado por el proliferador de peroxisomas para la mejora de la funcion cognitiva en pacientes con apolipoproteina e4 negativa |
| CR9848A CR9848A (es) | 2005-09-22 | 2008-03-28 | Combinacion de rosiglitazona y donepezil para mejorar la funcion cognitiva |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR9848A CR9848A (es) | 2005-09-22 | 2008-03-28 | Combinacion de rosiglitazona y donepezil para mejorar la funcion cognitiva |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20080226719A1 (OSRAM) |
| EP (2) | EP1926488A2 (OSRAM) |
| JP (2) | JP2009508960A (OSRAM) |
| KR (2) | KR20080056731A (OSRAM) |
| AR (2) | AR055649A1 (OSRAM) |
| AU (2) | AU2006295007A1 (OSRAM) |
| BR (2) | BRPI0616100A2 (OSRAM) |
| CA (2) | CA2623204A1 (OSRAM) |
| CR (2) | CR9849A (OSRAM) |
| EA (2) | EA200800879A1 (OSRAM) |
| IL (2) | IL190224A0 (OSRAM) |
| MA (2) | MA29872B1 (OSRAM) |
| NO (2) | NO20081847L (OSRAM) |
| PE (2) | PE20070618A1 (OSRAM) |
| TW (2) | TW200803851A (OSRAM) |
| WO (2) | WO2007038115A2 (OSRAM) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007299920A1 (en) * | 2006-09-19 | 2008-03-27 | Braincells, Inc. | PPAR Mediated Modulation of Neurogenesis |
| IL187159A0 (en) | 2007-07-03 | 2009-02-11 | Gur Megiddo | Use of metadoxine in relief of alcohol intoxication |
| WO2009043593A1 (en) * | 2007-10-05 | 2009-04-09 | Merz Pharma Gmbh & Co. Kgaa | Combination therapy using memantine and glitazones |
| EP2085120A1 (en) * | 2008-02-01 | 2009-08-05 | Merz Pharma GmbH & Co. KGaA | The use of substances for the treatment of central or peripheral insulin receptor impairment and insulin resistance |
| US8846315B2 (en) | 2008-08-12 | 2014-09-30 | Zinfandel Pharmaceuticals, Inc. | Disease risk factors and methods of use |
| PE20150362A1 (es) * | 2008-08-12 | 2015-03-20 | Zinfandel Pharmaceuticals Inc | Metodo de identificacion de factores de riesgo de la enfermedad |
| WO2010068750A2 (en) * | 2008-12-11 | 2010-06-17 | Board Of Trustees Of Leland Stanford Junior University | Compositons and method for treatment of mood and cognitive impairments |
| NZ597319A (en) * | 2009-06-25 | 2014-06-27 | Alcobra Ltd | A method for the treatment, alleviation of symptoms of, relieving, improving and preventing a cognitive disease, disorder or condition |
| US20100178307A1 (en) * | 2010-01-13 | 2010-07-15 | Jianye Wen | Transdermal anti-dementia active agent formulations and methods for using the same |
| US20130267560A1 (en) * | 2010-10-22 | 2013-10-10 | Cadila Healthcare Limited | Sustained release pharmaceutical compositions of donepezil |
| CA2824024A1 (en) * | 2011-01-10 | 2012-07-19 | Zinfandel Pharmaceuticals, Inc. | Tomm40 variants as genetic markers for alzheimer's disease |
| CA2824050A1 (en) | 2011-01-10 | 2012-07-19 | Zinfandel Pharmaceuticals, Inc. | Methods and drug products for treating alzheimer's disease |
| MX2014004679A (es) | 2011-10-21 | 2014-08-01 | Takeda Pharmaceutical | Preparacion de liberacion sostenida. |
| US20140294724A1 (en) * | 2011-10-24 | 2014-10-02 | Intellect Neurosciences, Inc. | Compositions and methods for treatment of proteinopathies |
| EP2987489A4 (en) * | 2013-04-19 | 2016-09-07 | Takeda Pharmaceutical | MEDICINAL FORMULATION WITH DELAYED RELEASE |
| US10391079B2 (en) * | 2016-07-26 | 2019-08-27 | Ausio Pharmaceuticals, Llc | Methods of diagnosing and treating Alzheimer's disease with S-equol |
| US20180153859A1 (en) * | 2016-12-02 | 2018-06-07 | T3D Therapeutics, Inc. | Methods of treating or preventing cognitive impairment using indane acetic acid derivatives based on apoe4 genotype |
| KR102142026B1 (ko) * | 2017-05-31 | 2020-08-06 | 주식회사 대웅제약 | 방출제어가 용이한 서방성 약물 미립자의 제조방법 |
| KR102224918B1 (ko) | 2018-03-20 | 2021-03-09 | (주)인벤티지랩 | 도네페질 및 메만틴을 포함하는 인지 장애 관련 질병의 예방 또는 치료용 약학적 복합 조성물 및 이의 제조 방법 |
| US12303604B1 (en) | 2024-10-16 | 2025-05-20 | Currax Pharmaceuticals Llc | Pharmaceutical formulations comprising naltrexone and/or bupropion |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE625212T1 (de) * | 1992-10-13 | 2000-11-02 | Duke University, Durham | Verfahren zum entdecken von krankheit von alzheimer. |
| US6191154B1 (en) * | 1998-11-27 | 2001-02-20 | Case Western Reserve University | Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases |
| ATE476978T1 (de) * | 1998-12-17 | 2010-08-15 | Mindset Biopharmaceuticals Usa | Verbesserung der geistigen fähigkeiten durch die steigerung der insulin-empfindlichkeit des gehirns |
| EP1718294A4 (en) * | 2004-01-30 | 2007-10-03 | Axonyx Inc | METHODS OF TREATING COMPLICATIONS OF DIABETES |
-
2006
- 2006-09-20 KR KR1020087009295A patent/KR20080056731A/ko not_active Withdrawn
- 2006-09-20 BR BRPI0616100-6A patent/BRPI0616100A2/pt not_active Application Discontinuation
- 2006-09-20 WO PCT/US2006/036603 patent/WO2007038115A2/en not_active Ceased
- 2006-09-20 CA CA002623204A patent/CA2623204A1/en not_active Abandoned
- 2006-09-20 EP EP06815011A patent/EP1926488A2/en not_active Withdrawn
- 2006-09-20 EA EA200800879A patent/EA200800879A1/ru unknown
- 2006-09-20 BR BRPI0616192-8A patent/BRPI0616192A2/pt not_active Application Discontinuation
- 2006-09-20 TW TW095134700A patent/TW200803851A/zh unknown
- 2006-09-20 TW TW095134699A patent/TW200803896A/zh unknown
- 2006-09-20 WO PCT/US2006/036597 patent/WO2007038112A2/en not_active Ceased
- 2006-09-20 KR KR1020087009286A patent/KR20080058413A/ko not_active Withdrawn
- 2006-09-20 EP EP06803887A patent/EP1940403A2/en not_active Withdrawn
- 2006-09-20 JP JP2008532341A patent/JP2009508960A/ja active Pending
- 2006-09-20 US US12/067,382 patent/US20080226719A1/en not_active Abandoned
- 2006-09-20 JP JP2008532338A patent/JP2009508959A/ja active Pending
- 2006-09-20 CA CA002623210A patent/CA2623210A1/en not_active Abandoned
- 2006-09-20 AU AU2006295007A patent/AU2006295007A1/en not_active Abandoned
- 2006-09-20 AU AU2006295010A patent/AU2006295010A1/en not_active Abandoned
- 2006-09-20 US US12/067,374 patent/US20080262047A1/en not_active Abandoned
- 2006-09-20 EA EA200800880A patent/EA200800880A1/ru unknown
- 2006-09-21 PE PE2006001145A patent/PE20070618A1/es not_active Application Discontinuation
- 2006-09-21 PE PE2006001143A patent/PE20070976A1/es not_active Application Discontinuation
- 2006-09-25 AR ARP060104149A patent/AR055649A1/es unknown
- 2006-09-25 AR ARP060104148A patent/AR056527A1/es unknown
-
2008
- 2008-03-17 IL IL190224A patent/IL190224A0/en unknown
- 2008-03-17 IL IL190217A patent/IL190217A0/en unknown
- 2008-03-28 CR CR9849A patent/CR9849A/es not_active Application Discontinuation
- 2008-03-28 CR CR9848A patent/CR9848A/es not_active Application Discontinuation
- 2008-04-15 MA MA30850A patent/MA29872B1/fr unknown
- 2008-04-15 MA MA30849A patent/MA29871B1/fr unknown
- 2008-04-16 NO NO20081847A patent/NO20081847L/no not_active Application Discontinuation
- 2008-04-16 NO NO20081843A patent/NO20081843L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AR055649A1 (es) | 2007-08-29 |
| KR20080056731A (ko) | 2008-06-23 |
| KR20080058413A (ko) | 2008-06-25 |
| US20080226719A1 (en) | 2008-09-18 |
| JP2009508959A (ja) | 2009-03-05 |
| CR9848A (es) | 2008-06-18 |
| US20080262047A1 (en) | 2008-10-23 |
| EA200800879A1 (ru) | 2008-10-30 |
| IL190224A0 (en) | 2008-11-03 |
| PE20070618A1 (es) | 2007-07-04 |
| JP2009508960A (ja) | 2009-03-05 |
| BRPI0616192A2 (pt) | 2011-06-14 |
| NO20081847L (no) | 2008-06-18 |
| TW200803896A (en) | 2008-01-16 |
| WO2007038115A3 (en) | 2007-12-13 |
| MA29871B1 (fr) | 2008-10-03 |
| WO2007038115A2 (en) | 2007-04-05 |
| PE20070976A1 (es) | 2007-12-05 |
| EP1940403A2 (en) | 2008-07-09 |
| AU2006295010A1 (en) | 2007-04-05 |
| IL190217A0 (en) | 2008-11-03 |
| CA2623204A1 (en) | 2007-04-05 |
| CA2623210A1 (en) | 2007-04-05 |
| WO2007038112A3 (en) | 2007-12-06 |
| EP1926488A2 (en) | 2008-06-04 |
| AU2006295007A1 (en) | 2007-04-05 |
| NO20081843L (no) | 2008-06-16 |
| TW200803851A (en) | 2008-01-16 |
| AR056527A1 (es) | 2007-10-10 |
| EA200800880A1 (ru) | 2009-02-27 |
| WO2007038112A2 (en) | 2007-04-05 |
| BRPI0616100A2 (pt) | 2011-06-07 |
| MA29872B1 (fr) | 2008-10-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR9849A (es) | Agonistas del receptor gamma activado por el proliferador de peroxisomas para la mejora de la funcion cognitiva en pacientes con apolipoproteina e4 negativa | |
| AR109995A2 (es) | Método para inhibir la resorción ósea | |
| BRPI0516727A (pt) | métodos para tratar um linfoma positivo em cd30 , para inibir o crescimento de uma célula que expressa cd30, e para tratar ou prevenir uma doença | |
| AR057631A1 (es) | Composiciones y metodos para incrementar la sensibilidad a insulina | |
| EA200702346A1 (ru) | КРИСТАЛЛИЧЕСКАЯ ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПИРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГИДРОФУРАН-3-ИЛОКСИ)БЕНЗИЛ]БЕНЗОЛА, СПОСОБ ЕЁ ПОЛУЧЕНИЯ И ЕЁ ПРИМЕНЕНИЕ ДЛЯ ПРИГОТОВЛЕНИЯ ЛЕКАРСТВЕННЫХ СРЕДСТВ | |
| AR058182A1 (es) | Metodos, composiciones y equipos par el tratamiento de afecciones medicas | |
| EA201101187A1 (ru) | Антидиабетические лекарственные средства, содержащие ингибитор dpp-4 (линаглиптин) необязательно в комбинации с другими антидиабетическими средствами | |
| CY1117925T1 (el) | Μεθοδος αγωγης και βιοπροσδιορισμος που σχετιζεται με παραγοντα αναστολης της μεταναστευσης των μακροφαγων (mif) ως προερχομενο απο την καρδια μυοκαρδιακο κατασταλτικο παραγοντα | |
| WO2009055001A3 (en) | Methods of treating aging and methods of screening candidate agents therefor | |
| EP2478901A3 (en) | Neurogenic compounds | |
| CY1116808T1 (el) | Συνθεση που περιλαμβανει σκονη μεμβρανης κελυφους αυγου για χρηση στην θεραπεια του διαβητη mellitus | |
| CO6390112A2 (es) | Método para el tratamiento de la enfermedad de parkinson usando un bacterófago filamentoso | |
| HN2008000906A (es) | Enzimas para reducir el estres inmulogico | |
| NI201000173A (es) | Uso de dronedarona o una sal aceptable farmacéuticamente de ésta, para la preparación de un medicamento para regular el nivel de potasio en la sangre. | |
| AR076113A1 (es) | Metodo o sistema que usa biomarcadores para el seguimiento de un tratamiento | |
| ES2582660T3 (es) | Sidnoniminas - inhibidores específicos de la recaptación de la dopamina y su uso en el tratamiento de los trastornos relacionados con la dopamina | |
| AR047726A1 (es) | Metodos y reactivos para el tratamiento de trastornos inflamatorios | |
| WO2006048877A3 (en) | Treatment of b-cell malignancies with fgfr3 inhibitors | |
| AR045423A1 (es) | Combinaciones de analiticos y antidepresivos | |
| MX391376B (es) | Composiciones de la membrana de la cáscara del huevo para usarse en el tratamiento de la cadena ligera kappa del factor nuclear de las células b activadas (nf-kb) en un organismo hospedero. | |
| EA200801297A1 (ru) | Способ снижения уровня постпрандиальной глюкозы | |
| TW200738255A (en) | Methods of regulating renalase (Monoamine Oxidase C) | |
| GB2447373A (en) | Compounds inducing differentiation of myoblasts or muscle fibers into neuron cells,pharmaceutical composition including said compounds. | |
| Mestre et al. | Comparison of two chemicals for removing an entocytherid (Ostracoda: Crustacea) species from its host crayfish (Cambaridae: Crustacea) | |
| Coppock | “Information Spillovers: Another Look at Experimental Estimates of Legislator Responsiveness”—CORRIGENDUM |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal (granting procedure) |